Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia 3Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Blast Crisis 2Neoplasms by Histologic Type 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Diseases 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Diseases 1

Interventions

fludarabine 4ibrutinib 2Rituximab 2Cyclophosphamide 2Alemtuzumab 2venetoclax 1ruxolitinib 1ponatinib 1ethanolamine oleate 1enzalutamide 1durvalumab 1dacetuzumab 1blinatumomab 1Valganciclovir 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tacrolimus 1Sulfamethoxazole 1Stem Cell Transplantation 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Pentetic Acid 1Lenalidomide 1Ganciclovir 1Ethanol 1Edetic Acid 1CA-4948 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoproliferative Disorders × ponatinib × Clear all
NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡